- Previous Close
69.90 - Open
70.05 - Bid 66.84 x 100
- Ask 67.13 x 100
- Day's Range
65.35 - 71.29 - 52 Week Range
20.84 - 71.29 - Volume
1,476,189 - Avg. Volume
895,175 - Market Cap (intraday)
7.012B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
53.11 - EPS (TTM)
1.26 - Earnings Date Feb 13, 2025 - Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
88.25
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
www.corcept.comRecent News: CORT
View MorePerformance Overview: CORT
Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CORT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CORT
View MoreValuation Measures
Market Cap
7.01B
Enterprise Value
6.64B
Trailing P/E
53.11
Forward P/E
31.15
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.86
Price/Book (mrq)
10.98
Enterprise Value/Revenue
10.56
Enterprise Value/EBITDA
45.94
Financial Highlights
Profitability and Income Statement
Profit Margin
22.56%
Return on Assets (ttm)
13.00%
Return on Equity (ttm)
25.77%
Revenue (ttm)
628.56M
Net Income Avi to Common (ttm)
140.49M
Diluted EPS (ttm)
1.26
Balance Sheet and Cash Flow
Total Cash (mrq)
380.34M
Total Debt/Equity (mrq)
1.06%
Levered Free Cash Flow (ttm)
140.11M